Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Dow
Queensland Health
Mallinckrodt
Deloitte
McKinsey
AstraZeneca
McKesson
Moodys

Generated: July 18, 2018

DrugPatentWatch Database Preview

Tedizolid phosphate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for tedizolid phosphate and what is the scope of tedizolid phosphate patent protection?

Tedizolid phosphate
is the generic ingredient in one branded drug marketed by Cubist Pharms Llc and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tedizolid phosphate has seventy-two patent family members in thirty-seven countries.

One supplier is listed for this compound.
Summary for tedizolid phosphate
International Patents:72
US Patents:3
Tradenames:1
Applicants:1
NDAs:2
Suppliers / Packagers: 1
Bulk Api Vendors: 32
Clinical Trials: 13
Patent Applications: 30
DailyMed Link:tedizolid phosphate at DailyMed
Pharmacology for tedizolid phosphate
Synonyms for tedizolid phosphate
((5R)-3-(3-Fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-2-oxooxazolidin-5- yl)methyl hydrogen phosphate
(R)-(3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-2-oxooxazol
(R)-(3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl dihydrogen phosphate
(R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one dihydrogenphosphate
[(5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl dihydrogen phosphate
[(5R)-3-{3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl dihydrogen phosphate
2-Oxazolidinone, 3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl)phenyl)-5- ((phosphonooxy)methyl)-, (5R)-
856867-55-5
9050AF
AKOS027250820
BDBM50017198
C17H16FN6O6P
CHEBI:83326
CHEMBL2105669
CS-5004
D09686
DB09042
DTXSID30234977
HY-14855B
idin-5-yl)methyl dihydrogen phosphate
KS-00000T77
MFCD28098176
MolPort-039-141-757
NE63553
O7DRJ6R4DW
s4641
SCHEMBL1557561
Sivextro
Sivextro (TN)
Tedizolid (phosphate)
Tedizolid phosphate (JAN/USAN)
Tedizolid phosphate [USAN]
Torezolid phosphate
TR-701
TR-701 FA
TR-701-FA
TR-701FA
UNII-O7DRJ6R4DW
ZINC43100953

US Patents and Regulatory Information for tedizolid phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc SIVEXTRO tedizolid phosphate TABLET;ORAL 205435-001 Jun 20, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Cubist Pharms Llc SIVEXTRO tedizolid phosphate POWDER;IV (INFUSION) 205436-001 Jun 20, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Cubist Pharms Llc SIVEXTRO tedizolid phosphate POWDER;IV (INFUSION) 205436-001 Jun 20, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Cubist Pharms Llc SIVEXTRO tedizolid phosphate POWDER;IV (INFUSION) 205436-001 Jun 20, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for tedizolid phosphate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,163,043 Oxazolidinone derivatives ➤ Try a Free Trial
9,624,250 Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for tedizolid phosphate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000078 Germany ➤ Try a Free Trial PRODUCT NAME: TEDIZOLID, GEGEBENENFALLS IN FORM EINES ESTERS, INSBESONDERE EINES PHOSPHATS, ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/991/001-003 20150323
90047-5 Sweden ➤ Try a Free Trial PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/991 20150325
834 Luxembourg ➤ Try a Free Trial PRODUCT NAME: TEDIZOLIDE, OPTIONNELLEMENT SOUS LA FORME D UN ESTER, EN PARTICULIER UN PHOSPHATE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150325
2015032 Lithuania ➤ Try a Free Trial PRODUCT NAME: TEDIZOLIDO FOSFATAS; REGISTRATION NO/DATE: EU/1/15/991 20150323
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Express Scripts
Citi
Cantor Fitzgerald
US Department of Justice
Chubb
UBS
Fuji
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.